Search
A vaccine to prevent rheumatic heart disease (RHD) and other life-threatening conditions caused by the common Strep A bacteria is a step closer thanks to funding announced by Minister for Indigenous Health, Hon Ken Wyatt AM, MP, in Perth today.
Optimising our national Covid-19 vaccine program could be one step closer thanks to new research now underway at The Kids Research Institute Australia investigating the most effective, long-term strategies for booster vaccinations.
Instant diagnosis and treatment of potentially life-threatening Strep A infections is now very close to reality across Australia’s remote and regional areas thanks to molecular point-of-care testing (POCT) that slashes result times from five days to just minutes.
Enrolments for Australia’s first needle-free, gene-based COVID-19 vaccine study – to be led in WA by The Kids Research Institute Australia – are open.
Congratulations to six researchers from The Kids Research Institute Australia, who will use valuable support from the Raine Medical Research Foundation’s 2024 grant round to undertake projects focused on improving the health and wellbeing of babies, children and young people.
Four The Kids Research Institute Australia researchers have received prestigious fellowships and four significant cohort studies led or co-led by The Kids have received key grants under two new funding programs supported by the State Government’s Future Health Research and Innovation (FHRI) Fund.
Researchers from The Kids Research Institute Australia and Curtin University will use a $3.9 million grant from the National Health and Medical Research Council to investigate whether a type of whooping cough vaccine could provide bonus protection against food allergies and eczema.
Influenza is the most common vaccine-preventable disease in Australia, causing significant morbidity and mortality. We assessed the burden of influenza across all ages in terms of influenza-associated mortality and hospitalizations using national mortality, hospital-discharge and influenza surveillance data.
In pediatric invasive candidiasis (IC), epidemiology and risk factors differ compared to adults. Furthermore, the use of antifungals in children is challenging and requires consideration of availability and tolerability of formulations, pharmacokinetic and pharmacodynamic variations, and safety in different age groups.
Christopher Blyth MBBS (Hons) DCH FRACP FRCPA PhD Centre Head, Wesfarmers Centre of Vaccines and Infectious Diseases; Co-Head, Infectious Diseases